1 week Ago By ABMN Staff
Corebridge Financial Inc. lessened its holdings in ArriVent BioPharma, Inc. ( NASDAQ:AVBP – Free Report ) by 7.
0% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 14,007 shares of the company’s stock after selling 1,057 shares during the period. Corebridge Financial Inc.
’s holdings in ArriVent BioPharma were worth $373,000 as of its most recent SEC filing. Several other large investors also recently added to or reduced their stakes in AVBP. Mirae Asset Global Investments Co.
Ltd. purchased a new stake in shares of ArriVent BioPharma during the 4th quarter valued at $31,000. KLP Kapitalforvaltning AS bought a new position in ArriVent BioPharma during the 4th quarter worth approximately $83,000.
China Universal Asset Management Co. Ltd. purchased a new position in shares of ArriVent BioPharma in the fourth quarter worth $190,000.
New York State Common Retirement Fund increased its holdings in ArriVent BioPharma by 34.6% during the 4th quarter. New York State Common Retirement Fund now owns 7,783 shares of the company’s stock valued at $207,000 after purchasing an additional 2,000 shares during the period.
Finally, The Manufacturers Life Insurance Company bought a new position in shares of ArriVent BioPharma during the third quarter valued at approximately $240,000. Institutional investors own 9.48% of the company’s stock.
ArriVent BioPharma Stock Up 7.7 % AVBP opened at $17.56 on Thursday.
ArriVent BioPharma, Inc. has a twelve month low of $14.35 and a twelve month high of $36.
37. The firm has a 50 day moving average price of $22.29 and a 200-day moving average price of $25.
95. The stock has a market capitalization of $597.32 million, a price-to-earnings ratio of -6.
83 and a beta of 1.66. Wall Street Analyst Weigh In Several brokerages have commented on AVBP.
HC Wainwright restated a “buy” rating and issued a $39.00 price objective on shares of ArriVent BioPharma in a report on Friday, March 7th. B.
Riley began coverage on shares of ArriVent BioPharma in a research note on Thursday, March 20th. They set a “buy” rating and a $37.00 price objective for the company.
Finally, Guggenheim started coverage on ArriVent BioPharma in a research report on Monday, March 10th. They issued a “buy” rating and a $45.00 price objective on the stock.
Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, ArriVent BioPharma currently has a consensus rating of “Buy” and an average target price of $39.00.
Get Our Latest Stock Analysis on AVBP ArriVent BioPharma Profile ( Free Report ) ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. See Also Want to see what other hedge funds are holding AVBP? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for ArriVent BioPharma, Inc. ( NASDAQ:AVBP – Free Report ). Receive News & Ratings for ArriVent BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArriVent BioPharma and related companies with MarketBeat.
com's FREE daily email newsletter ..
